ATE296112T1 - Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 - Google Patents

Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12

Info

Publication number
ATE296112T1
ATE296112T1 AT96910650T AT96910650T ATE296112T1 AT E296112 T1 ATE296112 T1 AT E296112T1 AT 96910650 T AT96910650 T AT 96910650T AT 96910650 T AT96910650 T AT 96910650T AT E296112 T1 ATE296112 T1 AT E296112T1
Authority
AT
Austria
Prior art keywords
colitis
substance
animal
antibodies
effectiveness
Prior art date
Application number
AT96910650T
Other languages
English (en)
Inventor
Warren Strober
Ivan Fuss
Markus Neurath
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE296112T1 publication Critical patent/ATE296112T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT96910650T 1995-10-25 1996-03-29 Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12 ATE296112T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/547,979 US5853697A (en) 1995-10-25 1995-10-25 Methods of treating established colitis using antibodies against IL-12
PCT/US1996/004337 WO1997015327A1 (en) 1995-10-25 1996-03-29 Methods of treating established colitis using antibodies against il-12

Publications (1)

Publication Number Publication Date
ATE296112T1 true ATE296112T1 (de) 2005-06-15

Family

ID=24186934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910650T ATE296112T1 (de) 1995-10-25 1996-03-29 Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12

Country Status (10)

Country Link
US (1) US5853697A (de)
EP (1) EP0862461B1 (de)
JP (2) JP4148533B2 (de)
AT (1) ATE296112T1 (de)
AU (1) AU710282B2 (de)
CA (1) CA2235866C (de)
DE (1) DE69634782T2 (de)
ES (1) ES2239329T3 (de)
MX (1) MX9803253A (de)
WO (1) WO1997015327A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780597A (en) * 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
CN101274962A (zh) * 1998-01-23 2008-10-01 霍夫曼-拉罗奇有限公司 人il-12抗体
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001042507A1 (en) * 1999-12-09 2001-06-14 Advanced Research & Technology Institute Fluorescent in situ rt-pcr
US6902734B2 (en) * 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20040197304A1 (en) * 2003-04-01 2004-10-07 The Procter & Gamble Company And Alimentary Health, Ltd. Methods of determining efficacy of treatments of inflammatory diseases of the bowel
MXPA06003663A (es) * 2003-10-03 2006-06-05 Pharmacia Corp Composiciones de un inhibidor selectivo de la ciclooxigenasa - 2 administrado en condiciones hipotermicas para el tratamiento de trastornos o lesion del sistema nervioso central mediados por isquemicos.
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
MY157915A (en) 2004-12-21 2016-08-15 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses.
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
EP2261323A1 (de) * 2005-05-31 2010-12-15 The Iams Company Probiotische Katzen-Laktobazillen
AU2006253007B2 (en) * 2005-05-31 2012-12-20 Alimentary Health Ltd Feline probiotic Bifidobacteria
EP1943359B1 (de) * 2005-09-30 2011-06-29 Centocor Ortho Biotech Inc. Zusammensetzungen und verfahren für il13-biomarker
KR20090100461A (ko) 2007-01-16 2009-09-23 아보트 러보러터리즈 건선의 치료방법
RU2436581C2 (ru) 2007-02-01 2011-12-20 Дзе Иамс Компани Способ уменьшения воспаления и снижения стресса у млекопитающего
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
KR20160116056A (ko) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
CN109071653A (zh) 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
CN117045784A (zh) 2016-12-14 2023-11-14 比奥拉治疗股份有限公司 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
EP3793521A4 (de) 2018-05-18 2022-02-23 Janssen Biotech, Inc. Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
IL326284A (en) 2018-09-24 2026-04-01 Janssen Biotech Inc A safe and effective method for treating ulcerative colitis with an anti-IL12/IL23 antibody
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE140483T1 (de) * 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
DE69034249T2 (de) * 1989-12-22 2008-05-29 F. Hoffmann-La Roche Ag Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor
CA2121096A1 (en) * 1993-04-22 1994-10-23 Weng Tao Monoclonal antibodies to bovine cytokines
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH0769895A (ja) * 1993-08-27 1995-03-14 Tokyo Tanabe Co Ltd 炎症性腸疾患治療剤
US5707622A (en) * 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases

Also Published As

Publication number Publication date
WO1997015327A1 (en) 1997-05-01
CA2235866A1 (en) 1997-05-01
EP0862461B1 (de) 2005-05-25
DE69634782T2 (de) 2006-03-23
AU710282B2 (en) 1999-09-16
EP0862461A1 (de) 1998-09-09
MX9803253A (es) 1998-09-30
JP4148533B2 (ja) 2008-09-10
JP2008169199A (ja) 2008-07-24
CA2235866C (en) 2010-09-28
JP2000502991A (ja) 2000-03-14
US5853697A (en) 1998-12-29
AU5378696A (en) 1997-05-15
DE69634782D1 (de) 2005-06-30
ES2239329T3 (es) 2005-09-16

Similar Documents

Publication Publication Date Title
ATE296112T1 (de) Methoden zur behandlung von vorhandener colitis durch verwendung von antikörper gegen il-12
Lawton et al. Some effects of high velocity electrons on wood
WO2005050200A3 (en) Screening assays and methods of tumor treatment
GB8916400D0 (en) Modified igg3
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
ATE452204T1 (de) Screening-methoden unter verwendung eines strukturmodells von fih
Gabriel et al. Prenatal Exposure to Cocaine Impairs Neuronal Coding of Attention and Discriminative Learning a
Mitra et al. Inhibition in the lateral septum increases sucrose intake and decreases anorectic effects of stress
Pearson et al. Immune depression in trypanosome‐infected mice. III. Suppressor cells
Rossi et al. Interleukin-1β and tumor necrosis factor-α production by human monocytes cultured with L-thyroxine and thyrocalcitonin: Relation to severe root shortening
Feuer et al. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates
Luster et al. Alterations of the antibody response following in utero exposure to diethylstilbestrol
Woo et al. Contribution of perineuronal nets to hyperexcitability in pilocarpine‐induced status epilepticus
Watterson et al. Validation of a method to assess ADHD-related impulsivity in animal models
Phipps An experimental study of the behavior of amphipods with respect to light intensity, direction of rays and metabolism
Sismondo Physical characteristics of the drumming of Meconema thalassinum
RU99111864A (ru) Способ обработки призабойной зоны пласта
DE60027273D1 (de) ASSAY ZUR IDENTIFIKATION VON IgE-ANTIKÖRPER-SUPPRESSOREN
Powell Probability of reinforcement and fixed-ratio responding: A model
RU95102036A (ru) Способ определения спонтанной двигательной активности крыс
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
JÍRA SOME ASPECTS OF DIAGNOSIS OF TOXOPLASMOSIS
Michaely et al. Metastatic pancreatic adenocarcinoma in a giraffe
RU97102373A (ru) Способ определения активности патологического процесса у больных рассеянным склерозом
SCHMITERLÖW Depressor and pressor activity of extracts from the aortic wall of cattle.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties